PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
LFCR Lifecore Biomedical
- 6.090
- +0.150+2.53%
Close Feb 14 16:00 ET
- 6.090
- 0.0000.00%
Post 16:00 ET
225.48MMarket Cap-11.28P/E (TTM)
6.230High5.970Low82.53KVolume5.980Open5.940Pre Close504.40KTurnover0.40%Turnover Ratio19.03P/E (Static)37.03MShares8.45052wk High14.60P/B125.74MFloat Cap3.67952wk Low--Dividend TTM20.65MShs Float16.750Historical High--Div YieldTTM4.38%Amplitude1.510Historical Low6.111Avg Price1Lot Size
Trending Stocks
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!
Lifecore Biomedical Stock Forum
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
Thursday, 19th December at 7:00 am
Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial
Lifecore to Leverage Differentiated Capabilities and Knowledge in Fill and Finish to Support Nirsum's NIH-Funded NRS-033 Development Program
CHASK...
Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO
Lifecore Biomedical has announced an amendment and extension of its asset-based lending revolving credit facility with BMO. The amendment extends the facility term by three years to November 2027, simplifies and reduces interest rates, and provides greater flexibility regarding covenants and reporting requirements. This follows the company's recent $24.3 million private placement financ...
Dow Jones· 1 min ago
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update
Lifecore Biomedical (NASDAQ: LFCR) reported its fiscal year 2024 results, showing strong revenue growth of 24.2% to $128.3 million.
The company's CDMO business grew 27%, while its HA raw material manufacturing increased 18%.
Gross profit rose 49.5% to $41.9 million, with margin expanding to 32.6%.
Key highlights include:
Net income from con...
$American International Group (AIG.US)$ $Bioventus (BVS.US)$ $CohBar (Delisted) (CWBR.US)$ $HeartCore Enterprises (HTCR.US)$ $Intuit (INTU.US)$ $Lifecore Biomedical (LFCR.US)$ $Lipocine (LPCN.US)$ $Microbot Medical (MBOT.US)$ $Ocean Biomedical (OCEA.US)$ $Palo Alto Networks (PANW.US)$ $RenaissanceRe Holdings (RNR.US)$ $SunCar technology (SDA.US)$ $Sysco Corp (SYY.US)$ $TEMA MONOPOLIES AND OLIGOPOLIES ETF (TOLL.US)$ $Western Digital (WDC.US)$
150M$ refinancing deal
No comment yet